Radiation
Radium 223
Radium 223 is a radiation therapy with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
RADIATION
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
2
67%
Ph phase_2
1
33%
Phase Distribution
2
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(2)
Terminated(1)
Detailed Status
Completed2
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (66.7%)
Phase 21 (33.3%)
Trials by Status
completed267%
withdrawn133%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_1
Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer
NCT03737370
completedphase_2
Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer
NCT02390934
withdrawnphase_1
A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer
NCT02396368
Clinical Trials (3)
Showing 3 of 3 trials
NCT03737370Phase 1
Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer
NCT02390934Phase 2
Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer
NCT02396368Phase 1
A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer
All 3 trials loaded
Drug Details
- Intervention Type
- RADIATION
- Total Trials
- 3